Brookmont Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-25,206
| Closed | -$2.15M | – | 57 |
|
|
2021
Q1 | $2.15M | Sell |
25,206
-377
| -1% | -$33.8K | 1.39% | 27 |
|
|
2020
Q4 | $2.42M | Sell |
25,583
-1,316
| -5% | -$115K | 1.7% | 22 |
|
|
2020
Q3 | $2.34M | Buy |
26,899
+584
| +2% | +$50.6K | 1.74% | 18 |
|
|
2020
Q2 | $2.3M | Sell |
26,315
-6,251
| -19% | -$540K | 1.84% | 16 |
|
|
2020
Q1 | $2.69M | Sell |
32,566
-2,590
| -7% | -$231K | 2.16% | 16 |
|
|
2019
Q4 | $3.33M | Sell |
35,156
-3,124
| -8% | -$280K | 1.99% | 22 |
|
|
2019
Q3 | $3.33M | Sell |
38,280
-8,102
| -17% | -$727K | 1.9% | 23 |
|
|
2019
Q2 | $4.24M | Sell |
46,382
-4,993
| -10% | -$423K | 2.55% | 9 |
|
|
2019
Q1 | $4.43M | Buy |
51,375
+66
| +0.1% | +$5.3K | 2.72% | 7 |
|
|
2018
Q4 | $3.94M | Buy |
51,309
+7,693
| +18% | +$599K | 2.69% | 7 |
|
|
2018
Q3 | $3.37M | Sell |
43,616
-183
| -0.4% | -$13.5K | 2.01% | 20 |
|
|
2018
Q2 | $2.96M | Buy |
43,799
+373
| +0.9% | +$25.7K | 1.87% | 22 |
|
|
2018
Q1 | $3.15M | Sell |
43,426
-50,599
| -54% | -$3.85M | 2.08% | 18 |
|
|
2017
Q4 | $7.07M | Buy |
94,025
+32,165
| +52% | +$2.43M | 3.05% | 11 |
|
|
2017
Q3 | $4.76M | Sell |
61,860
-53,857
| -47% | -$4.07M | 2.61% | 8 |
|
|
2017
Q2 | $8.65M | Sell |
115,717
-4,247
| -4% | -$301K | 3.26% | 12 |
|
|
2017
Q1 | $7.98M | Sell |
119,964
-1,451
| -1% | -$96.7K | 2.95% | 18 |
|
|
2016
Q4 | $7.92M | Sell |
121,415
-11,014
| -8% | -$714K | 3.12% | 17 |
|
|
2016
Q3 | $9.37M | Buy |
132,429
+783
| +0.6% | +$57.1K | 3.49% | 13 |
|
|
2016
Q2 | $9.73M | Sell |
131,646
-25,585
| -16% | -$1.77M | 3.55% | 12 |
|
|
2016
Q1 | $10.2M | Sell |
157,231
-210
| -0.1% | -$14.3K | 3.27% | 15 |
|
|
2015
Q4 | $12.1M | Sell |
157,441
-3,559
| -2% | -$283K | 3.45% | 5 |
|
|
2015
Q3 | $13.3M | Sell |
161,000
-13,445
| -8% | -$1.2M | 3.79% | 2 |
|
|
2015
Q2 | $15.4M | Sell |
174,445
-716
| -0.4% | -$65.7K | 3.89% | 2 |
|
|
2015
Q1 | $15.5M | Buy |
175,161
+15,986
| +10% | +$1.42M | 3.88% | 2 |
|
|
2014
Q4 | $13.2M | Sell |
159,175
-27,982
| -15% | -$2.32M | 3.82% | 2 |
|
|
2014
Q3 | $15.8M | Sell |
187,157
-12,026
| -6% | -$973K | 4.04% | 2 |
|
|
2014
Q2 | $16.2M | Buy |
199,183
+18,860
| +10% | +$1.48M | 3.89% | 4 |
|
|
2014
Q1 | $13.7M | Sell |
180,323
-2,939
| -2% | -$214K | 3.78% | 3 |
|
|
2013
Q4 | $13.2M | Buy |
183,262
+29,339
| +19% | +$2.04M | 3.64% | 8 |
|
|
2013
Q3 | $10.6M | Buy |
153,923
+61,029
| +66% | +$4.04M | 3.44% | 6 |
|
|
2013
Q2 | $5.89M | Buy |
+92,894
| New | +$6.04M | 2.44% | 29 |
|
Other funds holding NVS
Brookmont Capital Management's NVS Position: Q2 2021 in Review
Brookmont Capital Management sold out of Novartis (NVS) in Q2 2021, closing a stake of 25,206 shares — an estimated $2.15M sold.
Brookmont Capital Management first reported a position in NVS in Q2 2013 and held it in 32 quarters. The position peaked at $16.2M in Q2 2014. 1,120 funds tracked by Wall St. Rank hold NVS as of Q2 2021.
- Brookmont Capital Management reported no remaining Novartis position as of Q2 2021 after selling out during the quarter.
- Brookmont Capital Management sold 25,206 Novartis shares in Q2 2021, an estimated $2.15M.
- Brookmont Capital Management first reported a position in Novartis in Q2 2013 and held it in 32 quarters.
- Brookmont Capital Management's Novartis position peaked at $16.2M in Q2 2014.
- 1,120 funds tracked by Wall St. Rank held Novartis as of Q2 2021.
Based on Brookmont Capital Management's 13F filing for Q2 2021, filed 19 Jul 2021.